Publications: Media Center

Newly Updated! Arterial Restenosis Clinical and Industry Report by The Next Phase -- Winter 2002

REDMOND, Wash.--(BW HealthWire)--Feb. 12, 2002-- "Coronary and Peripheral Artery Restenosis: Developments and Trends in Prevention and Treatment'' is a global Situational Market Analysis(TM) (SMA(TM)) Report published by The Next Phase Consultancy at: www.TheNextPhase.com/

Subscribers to SMA Restenosis Report receive two free updates per year with the purchase of an annual subscription. This report is the only one of its kind covering restenosis therapies in all of the biomedical industries -- pharmaceuticals, biotech and medical devices. It contains analysis of 140 technologies and more than 400 globally available and developing interventional therapies from 160 companies and research institutions.

RESTENOSIS following interventional treatment for coronary or peripheral artery disease has persisted for more than 20 years. Drug-eluting stents, along with hundreds of other restenosis therapies, are now in development to prevent or treat this complicated condition. An in-depth restenosis market report update, new for WINTER 2002, is now available from The Next Phase® Consultancy. This "living'' market report will keep healthcare industry executives informed of emerging products and technologies in the dynamic restenosis marketplace.

"Coronary and Peripheral Artery Restenosis: Developments and Trends in Prevention and Treatment'' consists of two volumes. The first comprises an industry overview and the second contains the unique SMArt Chart(TM) section. The complete study has more than 300 pages of information with over 45 figures and tables, a glossary of terms, and an alphabetical subject index.

"Manufacturers have targeted restenosis rates of less than 5%, and drug eluting stents are on track to capture this position,'' asserts Victoria Hunsicker Sanko, President of The Next Phase. "Our SMA Restenosis Report, unlike any other, keeps our subscribers apprised of the latest global technology and market developments.''

Major modalities covered include Systemic Drug Delivery, Local Drug Delivery, Medical Devices, Gene Therapy and Other Advanced Therapies. The Winter 2002 SMA Restenosis Report Update addresses several key issues including the development status of drug-eluting stents, therapeutic ultrasound, gene medicines, and other promising technologies. The future role of brachytherapy in the prevention of restenosis is also discussed.

Here is what one satisfied customer had to say about the SMA Restenosis Report: "Let me say again what a tremendous job your team has done! It is a huge amount of work, extremely thorough and well laid out. The purchase has been a very worthwhile investment. I will be briefing our board of directors next week on strategic investment opportunities for our company in this area and the data you have summarized has been invaluable in preparing for this.''

For more information, including the Volume I "Core Report'' Table of Contents, the Volume II ``SMArt Chart'' Index, and ordering information, visit http://www.thenextphase.com/ or e-mail .

Contact:
The Next Phase(R) Consultancy, Redmond
Victoria Hunsicker Sanko, 425/869-8724
Fax 425/869-9397

Last modified February 18, 2004

SERVICES | EXPERIENCE | PUBLICATIONS | ABOUT US | OUTSIDE U.S.
Our Partners | Search | Contact | Privacy | Home

The Next Phase Consultancy, Inc.
Phone: 425.869.8724 / Fax: 425.869.9397
e-mail:

Trademark information:
The Next Phase and The Next Phase "Moons" logo are registered trademarks, and The Next Phase SMArt Chart, CPI, PTMA, SMA, TNP and TNP SMArt Chart are trademarks of The Next Phase Consultancy, Inc. Send mail to , with questions or comments about this web site.

Copyright © 2007 The Next Phase Consultancy, Inc. All rights reserved.